Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
Lilly breakthrough offers real hope for people with early Alzheimer's
17 July 2023
Biotechnology
The week in pharma: action, reaction and insight – week to July 21, 2023
23 July 2023
Pharmaceutical
Lilly tops pharma in market cap after 36% growth
21 August 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Companies featured in this story

More ones to watch >


Today's issue

Ring expands global R&D efforts with new Singapore partnerships
Biotechnology
Ring expands global R&D efforts with new Singapore partnerships
5 November 2024
Pharmaceutical
EU sets date for decision on proposed $16.5 billion Catalent buy
5 November 2024
Pharmaceutical
AstraZeneca sees progress in obesity drug trials, highlights new oral option
5 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
The Pharma Letter M&A roundup - October 2024
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Ring expands global R&D efforts with new Singapore partnerships
5 November 2024
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze